Donald Trump accused Hillary Clinton of making "one of the most brazen attempt at distraction in the history of politics," NBC reports.
The order applies to any new emails between Clinton and the White House related to the 2012 attack in Benghazi, Libya.
State pension funds are looking at a $1 trillion shortfall in what they owe workers in benefits, according to new data from The Pew Charitable Trusts.
If Mylan's CEO wants to lower the price of the EpiPen today, she could, Express Scripts' Dr. Steve Miller says.
Aggressive marketing tactics have led to the overall perception that the EpiPen is essential. NBC News reports.
Jim Cramer explained why he chooses not to speculate the Fed when he makes the next investment for his charitable trust.
A rate hike from the Fed could spark an Asian stocks sell-off and trigger capital outflows in China, according to Macquarie IM.
El-Erian made his comments ahead of Fed Chair Janet Yellen's speech, scheduled for Friday morning in Jackson Hole, Wyoming.
Asia opened lower on Friday, after most local markets remained near-unchanged this week ahead of a speech by the Fed chair.
How should investors make money in a low-volatility, low-volume market? The answer may be taking defensive measures.
How an iPhone could be completely compromised with the tap of a finger.
Jim Cramer says it's time for Apple to put its massive $231 billion cash hoard to work, and buy this company.
CNBC's Rick Santelli and Robert Laszewski discuss what's wrong with Obamacare.
Donald Trump's pivot to Mr. Nice Guy must've completely freaked out Hillary Clinton, says Jake Novak—enough so that she felt the need to remind the world of all the bad things he's said!
Hillary Clinton has opened up a 10-point national lead over Donald Trump, a new poll suggests.
Brazilian police recommended on Thursday that prosecutors present charges against Ryan Lochte for a false crime report.
New rules from the Department of Labor may make retirement plans available to more workers.
CNBC's Meg Tirrell reports the latest on the drug price debate, Teva on a generic EpiPen and the FDA. David Maris, Wells Fargo analyst, and the "FMHR" traders weigh in.
The FDA and Congress enabled Mylan to secure a monopoly on EpiPens and then jack up the prices, says this intellectual-property expert. So why can't they just end it?